Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient

International Journal of Clinical Oncology

Volumn 15, Issue 5, 2010, Pages 508-511

  Maeda, Takahiro ^a   Kikuchi, Eiji ^a   Matsumoto, Kazuhiro ^a   Yazawa, Satoshi ^a   Hagiuda, Jun ^a   Miyajima, Akira ^a   Nakagawa, Ken ^a   Fujiwara, Hirokazu ^a   Hoshino, Haruhiko ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Bladder carcinoma; Cisplatin; Consciousness disturbance; Gemcitabine; Reversible posterior leukoencephalopathy syndrome

Indexed keywords

ANTICONVULSIVE AGENT; CISPLATIN; FENTANYL; GEMCITABINE; NEUROPROTECTIVE AGENT;

ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; BLADDER CARCINOMA; BONE METASTASIS; BONE PAIN; BRAIN EDEMA; CANCER PATIENT; CASE REPORT; COMA; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMAN; HYPERCALCEMIA; LYMPH NODE METASTASIS; MALAISE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; THALAMUS; UNCONSCIOUSNESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; FATAL OUTCOME; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS;

EID: 78149357871     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0068-3     Document Type: Article

References (9)

1. DJ Covarrubias PH Luetmer NG Campeau 2002 Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images AJNR Am J Neuroradiol 23 1038 1048 12063238
2. J Hinchey C Chaves B Appignani, et al. 1996 A reversible posterior leukoencephalopathy syndrome N Engl J Med 334 494 500 1:STN:280: DyaK287lslSisQ%3D%3D 10.1056/NEJM199602223340803 8559202 (Pubitemid 26067737)
3. DM Pinedo F Shah-Khan PC Shah 2007 Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin J Clin Oncol 25 5320 5321 10.1200/JCO.2007.13.5954 18024878 (Pubitemid 350232266)
4. FO Larsen SW Hansen 2004 Severe neurotoxicity caused by gemcitabine treatment Acta Oncol 43 590 591 10.1080/02841860410018494 15370618 (Pubitemid 39318560)
5. WS Bartynski 2008 Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features AJNR Am J Neuroradiol 29 1036 1042 1:STN:280:DC%2BD1cznsFSmsw%3D%3D 10.3174/ajnr.A0928 18356474 (Pubitemid 351954863)
6. S Sugimoto YL Yamamoto S Nagahiro, et al. 1995 Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats J Neurooncol 24 229 240 1:STN:280:DyaK28%2FovVGjtQ%3D%3D 10.1007/BF01052839 7595753
7. A Rajasekhar TJ George Jr 2007 Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature Oncologist 12 1332 1335 1:CAS:528:DC%2BD1cXivVShtw%3D%3D 10.1634/theoncologist. 12-11-1332 18055853 (Pubitemid 350232606)
8. CA Dasanu 2008 Gemcitabine: vascular toxicity and prothrombotic potential Expert Opin Drug Saf 7 703 716 1:CAS:528:DC%2BD1cXhtlaisrfE 10.1517/14740330802374262 18983217
9. CJ Vaughan N Delanty 2000 Hypertensive emergencies Lancet 356 411 417 1:STN:280:DC%2BD3cvjtVCiuw%3D%3D 10.1016/S0140-6736(00)02539-3 10972386